SIM0388
Phase 1Small molecule
Jiangsu Simcere Pharmaceutical Co., Ltd.SIM0388 is one of 36 small molecule programs targeting Ascites. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
52 competitors in Ascites
#DrugCompanyPhaseTrials
1Aldactone
PfizerApproved
Samsca
OtsukaApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Sandostatin
NovartisPhase 3
Glypressin
MMallinckrodt
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Farxiga
AstraZenecaPhase 2
Catumaxomab
NNeovii Biotech
Phase 3
Sutent
PfizerPhase 2
Eylea
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SIM0388. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details